

For Immediate Release

TSX Symbol: **RVX****Resverlogix Corp. Announces Live Webcast Update**

CALGARY, AB, July 24, 2006 – ResVerlogix Corp. (“Resverlogix”) (TSX: RVX), an emerging international leader in cardiovascular research, announced today that it will host a live webcast on Monday July 31, 2006 at 10:00 am MST. The webcast will allow securities analysts, shareholders, media and other key stakeholders the opportunity to hear from Dr. Jan Johansson, Sr. Vice-President Clinical Affairs and Donald McCaffrey, President & CEO discuss the Company's strategic direction of its scientific and corporate programs.

The call is being webcast by Vcall and can be accessed at a link provided on “**Resverlogix’s**” website at [www.resverlogix.com](http://www.resverlogix.com). Investors can also access the webcast at [www.InvestorCalendar.com](http://www.InvestorCalendar.com).

The web cast will be available on our website for replay throughout 2006. The web cast link will be posted on the Resverlogix web site [www.resverlogix.com](http://www.resverlogix.com) prior to the event.

**About Resverlogix Corp.**

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NexVas™, applies advanced medical research to develop therapies that increase ApoA-I the key protein of high density lipoprotein (HDL), the "good cholesterol," and other targets to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: [www.resverlogix.com](http://www.resverlogix.com).

*This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.*

**For further information please contact:**

**Theresa E. Kennedy**  
VP Corporate Communications  
Resverlogix Corp.  
Phone: 604-538-7072  
Fax: 403-256-8495  
Email: [theresa@resverlogix.com](mailto:theresa@resverlogix.com)

**Kenneth Lebioda**  
Vice President Business Development  
Resverlogix Corp.  
Phone: 403-254-9252 ext. 227  
Fax: 403-256-8495  
Email: [ken@resverlogix.com](mailto:ken@resverlogix.com)